RxDoctor Payments Data

Adrian Kochno, DO

Internal Medicine · Bradenton, FLNPI 1871080416

Payments from drug & device makers

$1,030in general payments, 2019–2025

Across 38 payments — averaging $27.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$206
  • AstraZeneca$199
  • Merck$114
  • AbbVie$98
  • Novo Nordisk$75
  • Pfizer$70
  • plus $267 from 8 others

What the payments were for

  • Food & beverage$1,030100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,030 in reported general payments places this provider in the 70th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$119,167
Medicare patients
360
Services billed
1,862

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban265$87,932
Trelegy ElliptaFluticasone/Umeclidin/Vilanter22$14,805
OzempicSemaglutide14$13,626
TrulicityDulaglutide11$11,666
XareltoRivaroxaban25$8,658
NuedextaDextromethorphan Hbr/Quinidine11$8,580
JardianceEmpagliflozin15$7,220
Daptomycin19$6,764
LinzessLinaclotide12$6,740
MyrbetriqMirabegron17$6,231
FarxigaDapagliflozin Propanediol12$5,800
JanumetSitagliptin Phos/Metformin Hcl17$5,052
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog57$4,526
SantylCollagenase Clostridium Hist.14$4,444
Glucagon Emergency KitGlucagon12$3,598

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$70$87,932265 claims
Novo NordiskOzempic, Levemir, Novolog$75$16,69046 claims
Boehringer IngelheimJardiance$57$7,22015 claims
AbbVieLinzess$98$6,74012 claims
AstraZenecaFarxiga$199$5,80012 claims
MerckJanumet$114$5,05217 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Bradenton

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →